Transglutaminases in neurodegenerative disorders

Progress in Experimental Tumor Research

Volumn 38, Issue , 2005, Pages 139-157

  Bailey, Craig D C ^a   Tucholski, Janusz ^a   Johnson, Gail V W ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL; APOPTOSIS; BIOLOGICAL MODEL; CYTOLOGY; DEGENERATIVE DISEASE; ENZYMOLOGY; GENE EXPRESSION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; HUNTINGTON CHOREA; NERVE CELL; NERVE DEGENERATION; NERVOUS SYSTEM; NERVOUS SYSTEM INJURY; PARKINSON DISEASE; PHYSIOLOGY; REVIEW;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; APOPTOSIS; GENE EXPRESSION; HUMANS; HUNTINGTON DISEASE; MODELS, BIOLOGICAL; NERVE DEGENERATION; NERVOUS SYSTEM; NEURODEGENERATIVE DISEASES; NEURONS; PARKINSON DISEASE; TRANSGLUTAMINASES; TRAUMA, NERVOUS SYSTEM;

EID: 14544281981     PISSN: 00796263     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000084238     Document Type: Review

References (120)

1. Lorand L, Graham RM: Transglutaminases: Crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol 2003;4:140-156.
2. Maggio N, Sellitti S, Capano CP, Papa M: Tissue-transglutaminase in rat and human brain: Light and electron immunocytochemical analysis and in situ hybridization study. Brain Res Bull 2001; 56:173-182.
3. Kim SY, Grant P, Lee JH, Pant HC, Steinert PM: Differential expression of multiple transglutaminases in human brain. Increased expression and cross-linking by transglutaminases 1 and 2 in Alzheimer's disease. J Biol Chem 1999;274:30715-30721.
4. Mastroberardino PG, Iannicola C, Nardacci R, Bernassola F, De L, V, Melino G, Moreno S, Pavone F, Oliverio S, Fesus L, Piacentini M: 'Tissue' transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease. Cell Death Differ 2002;9: 873-880.
5. Candi E, Paradisi A, Terrinoni A, Pietroni V, Oddi S, Cadot B, Jogini V, Meiyappan M, Clardy J, Finazzi-Agro A, Melino G: Transglutaminase 5 is regulated by guanine-adenine nucleotides. Biochem J 2004;381:313-319.
6. Lesort M, Tucholski J, Miller ML, Johnson GV: Tissue transglutaminase: A possible role in neurodegenerative diseases. Prog Neurobiol 2000;61:439-463.
7. Achyuthan KE, Greenberg CS: Identification of a guanosine triphosphate-binding site on guinea pig liver transglutaminase. Role of GTP and calcium ions in modulating activity. J Biol Chem 1987;262:1901-1906.
8. Mishra S, Murphy LJ: Tissue transglutaminase has intrinsic kinase activity: Identification of transglutaminase 2 as an insulin-like growth factor-binding protein-3 kinase. J Biol Chem 2004; 279:23863-23868.
9. Nakaoka H, Perez DM, Baek KJ, Das T, Husain A, Misono K, Im MJ, Graham RM: Gh: A GTP-binding protein with transglutaminase activity and receptor signaling function. Science 1994;264: 1593-1596.
10. Ahvazi B, Boeshans KM, Idler W, Baxa U, Steinert PM, Rastinejad F: Structural basis for the coordinated regulation of transglutaminase 3 by guanine nucleotides and calcium/magnesium. J Biol Chem 2004;279:7180-7192.
11. Ahvazi B, Boeshans KM, Steinert PM: Crystal structure of transglutaminase 3 in complex with GMP: Structural basis for nucleotide specificity. J Biol Chem 2004;279:26716-26725.
12. Citron BA, Suo Z, SantaCruz K, Davies PJ, Qin F, Festoff BW: Protein crosslinking, tissue transglutaminase, alternative splicing and neurodegeneration. Neurochem Int 2002;40:69-78.
13. Junn E, Ronchetti RD, Quezado MM, Kim SY, Mouradian MM: Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 2003;100:2047-2052.
14. Zemaitaitis MO, Kim SY, Halverson RA, Troncoso JC, Lee JM, Muma NA: Transglutaminase activity, protein, and mRNA expression are increased in progressive supranuclear palsy. J Neuropathol Exp Neurol 2003;62:173-184.
15. Festoff BW, SantaCruz K, Arnold PM, Sebastian CT, Davies PJ, Citron BA: Injury-induced 'switch' from GTP-regulated to novel GTP-independent isoform of tissue transglutaminase in the rat spinal cord. J Neurochem 2002;81:708-718.
16. Tolentino PJ, DeFord SM, Notterpek L, Glenn CC, Pike BR, Wang KK, Hayes RL: Upregulation of tissue-type transglutaminase after traumatic brain injury. J Neurochem 2002;80: 579-588.
17. Tolentino PJ, Waghray A, Wang KK, Hayes RL: Increased expression of tissue-type transglutaminase following middle cerebral artery occlusion in rats. J Neurochem 2004;89:1301-1307.
18. Fesus L: Transglutaminase-catalyzed protein cross-linking in the molecular program of apoptosis and its relationship to neuronal processes. Cell Mol Neurobiol 1998;18:683-694.
19. Melino G, Piacentini M: 'Tissue' transglutaminase in cell death: A downstream or a multifunctional upstream effector? FEBS Lett 1998;430:59-63.
20. Tucholski J, Lesort M, Johnson GV: Tissue transglutaminase is essential for neurite outgrowth in human neuroblastoma SH-SY5Y cells. Neuroscience 2001;102:481-491.
21. Tucholski J, Johnson GV: Tissue transglutaminase directly regulates adenylyl cyclase resulting in enhanced cAMP-response element-binding protein (CREB) activation. J Biol Chem 2003;278: 26838-26843.
22. Maccioni RB, Arechaga J: Transglutaminase (TG) involvement in early embryogenesis. Exp Cell Res 1986;167:266-270.
23. Maccioni RB, Seeds NW: Transglutaminase and neuronal differentiation. Mol Cell Biochem 1986;69:161-168.
24. Zhang J, Lesort M, Guttmann RP, Johnson GV: Modulation of the in situ activity of tissue transglutaminase by calcium and GTP. J Biol Chem 1998;273:2288-2295.
25. Pahlman S, Ruusala AI, Abrahamsson L, Mattsson ME, Esscher T: Retinoic acid-induced differentiation of cultured human neuroblastoma cells: A comparison with phorbolester-induced differentiation. Cell Differ 1984;14:135-144.
26. Singh US, Pan J, Kao YL, Joshi S, Young KL, Baker KM: Tissue transglutaminase mediates activation of RhoA and MAP kinase pathways during retrnoic acid-induced neuronal differentiation of SH-SY5Y cells. J Biol Chem 2003;278:391-399.
27. Mahoney SA, Perry M, Seddon A, Bohlen P, Haynes L: Transglutaminase forms midkine homodimers in cerebellar neurons and modulates the neurite-outgrowth response. Biochem Biophys Res Commun 1996;224:147-152.
28. Mahoney SA, Wilkinson M, Smith S, Haynes LW: Stabilization of neuntes in cerebellar granule cells by transglutaminase activity: Identification of midkine and galectin-3 as substrates. Neuroscience 2000;101:141-155.
29. Rydel RE, Greene LA: cAMP analogs promote survival and neurite outgrowth in cultures of rat sympathetic and sensory neurons independently of nerve growth factor. Proc Natl Acad Sci USA 1988;85:1257-1261.
30. Mena MA, Casarejos MJ, Bonin A, Ramos JA, Garcia YJ: Effects of dibutyryl cyclic AMP and retinoic acid on the differentiation of dopamine neurons: Prevention of cell death by dibutyryl cyclic AMP. J Neurochem 1995;65:2612-2620.
31. Ciani E, Guidi S, Della VG, Perini G, Bartesaghi R, Contestabile A: Nitric oxide protects neuroblastoma cells from apoptosis induced by serum deprivation through cAMP-response element-binding protein (CREB) activation. J Biol Chem 2002;277:49896-49902.
32. Ahn S, Olive M, Aggarwal S, Krylov D, Ginty DD, Vinson C: A dominant-negative inhibitor of CREB reveals that it is a general mediator of stimulus-dependent transcription of c-fos. Mol Cell Biol 1998;18:967-977.
33. Gunning PW, Letourneau PC, Landreth GE, Shooter EM: The action of nerve growth factor and dibutyryl adenosine cyclic 3′:5′-monophosphate on rat pheochromocytoma reveals distinct stages in the mechanisms underlying neurite outgrowth. J Neurosci 1981;1:1085-1095.
34. Rudolph D, Tafuri A, Gass P, Hammerling GJ, Arnold B, Schutz G: Impaired fetal T cell development and perinatal lethality in mice lacking the cAMP response element binding protein. Proc Natl Acad Sci USA 1998;95:4481-4486.
35. Lonze BE, Riccio A, Cohen S, Ginty DD: Apoptosis, axonal growth defects, and degeneration of peripheral neurons in mice lacking CREB. Neuron 2002;34:371-385.
36. Piacentini M, Fesus L, Farrace MG, Ghibelli L, Piredda L, Melino G: The expression of 'tissue' transglutaminase in two human cancer cell lines is related with the programmed cell death (apoptosis). Eur J Cell Biol 1991;54:246-254.
37. Melino G, Annicchiarico-Petruzzelli M, Piredda L, Candi E, Gentile V, Davies PJ, Piacentini M: Tissue transglutaminase and apoptosis: Sense and antisense transfection studies with human neuroblastoma cells. Mol Cell Biol 1994;14:6584-6596.
38. Tucholski J, Johnson GV: Tissue transglutaminase differentially modulates apoptosis in a stimuli-dependent manner. J Neurochem 2002;81:780-791.
39. Gentile V, Thomazy V, Piacentini M, Fesus L, Davies PJ: Expression of tissue transglutaminase in Balb-C 3T3 fibroblasts: Effects on cellular morphology and adhesion. J Cell Biol 1992;119: 463-474.
40. Milakovic T, Tucholski J, McCoy E, Johnson GV: Intracellular localization and activity state of tissue transglutaminase differentially impacts cell death. J Biol Chem 2004;279: 8715-8722.
41. Oliverio S, Amendola A, Rodolfo C, Spinedi A, Piacentini M: Inhibition of 'tissue' transglutaminase increases cell survival by preventing apoptosis. J Biol Chem 1999;274:34123-34128.
42. Buommino E, Pasquali D, Sinisi AA, Bellastella A, Morelli F, Metafora S: Sodium butyrate/retinoic acid costimulation induces apoptosis-independent growth arrest and cell differentiation in normal and ras-transformed seminal vesicle epithelial cells unresponsive to retinoic acid. J Mol Endocrinol 2000;24:83-94.
43. Antonyak MA, Singh US, Lee DA, Boehm JE, Combs C, Zgola MM, Page RL, Cerione RA: Effects of tissue transglutaminase on retinoic acid-induced cellular differentiation and protection against apoptosis. J Biol Chem 2001;276:33582-33587.
44. De Laurenzi V, Melino G: Gene disruption of tissue transglutaminase. Mol Cell Biol 2001;21: 148-155.
45. Nanda N, Iismaa SE, Owens WA, Husain A, Mackay F, Graham RM: Targeted inactivation of Gh/tissue transglutaminase II. J Biol Chem 2001;276:20673-20678.
46. Boehm JE, Singh U, Combs C, Antonyak MA, Cerione RA: Tissue transglutaminase protects against apoptosis by modifying the tumor suppressor protein p110 Rb. J Biol Chem 2002;277: 20127-20130.
47. Chau BN, Wang JY: Coordinated regulation of life and death by RB. Nat Rev Cancer 2003;3: 130-138.
48. Kahlem P, Green H, Djian P: Transglutaminase action imitates Huntington's disease: Selective polymerization of Huntingtin containing expanded polyglutamine. Mol Cell 1998;1:595-601.
49. Karpuj MV Garren H, Slunt H, Price DL, Gusella J, Becher MW, Steinman L: Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei. Proc Natl Acad Sci USA 1999;96:7388-7393.
50. Dudek SM, Johnson GV: Transglutaminase catalyzes the formation of sodium dodecyl sulfate-insoluble, Alz-50-reactive polymers of tau. J Neurochem 1993;61:1159-1162.
51. Miller ML, Johnson GV: Transglutaminase cross-linking of the tau protein. J Neurochem 1995;65:1760-1770.
52. Bailey CD, Johnson GV: Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms. J Neurochem 2005; 92:83-92.
53. Lai TS, Tucker T, Burke JR, Strittmatter WJ, Greenberg CS: Effect of tissue transglutaminase on the solubility of proteins containing expanded polyglutamine repeats. J Neurochem 2004;88: 1253-1260.
54. Nemes Z, Devreese B, Steinert PM, Van Beeumen J, Fesus L: Cross-linking of ubiquitin, HSP27, parkin, and alpha-synuclein by gamma-glutamyl-epsilon- lysine bonds in Alzheimer's neurofibrillary tangles. FASEB J 2004;18:1135-1137.
55. Vonsattel JP, DiFiglia M: Huntington disease. J Neuropathol Exp Neurol 1998;57:369-384.
56. The Huntington's Disease Collaborative Research Group: A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72: 971-983.
57. Cooper JK, Schilling G, Peters MF, Herring WJ, Sharp AH, Kaminsky Z, Masone J, Khan FA, Delanoy M, Borchelt DR, Dawson VL, Dawson TM, Ross CA: Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Hum Mol Genet 1998;7:783-790.
58. Kegel KB, Meloni AR, Yi Y, Kim YJ, Doyle E, Cuiffo BG, Sapp E, Wang Y, Qui ZH, Chen JD, Nevins JR, Aronin N, DiFiglia M: Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J Biol Chem 2002;277:7466-7476.
59. Kim YJ, Yi Y, Sapp E, Wang Y, Cuiffo B, Kegel KB, Qin ZH, Aronin N, DiFiglia M: Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis. Proc Natl Acad Sci USA 2001;98:12784-12789.
60. Li SH, Li XJ: Aggregation of N-terminal huntingtin is dependent on the length of its glutamine repeats. Hum Mol Genet 1998;7:777-782.
61. Sapp E, Penney J, Young A, Aronin N, Vonsattel JP, DiFiglia M: Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease. J Neuropathol Exp Neurol 1999;58:165-173.
62. Ross CA: Polyglutamine pathogenesis: Emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron 2002;35:819-822.
63. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, Scherzinger E, Wanker EE, Mangiarini L, Bates GP: Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997;90:537-548.
64. Scherzinger E, Lurz R, Turmaine M, Mangiarini L, Hollenbach B, Hasenbank R, Bates GP, Davies SW, Lehrach H, Wanker EE: Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 1997;90:549-558.
65. Yang W, Dunlap JR, Andrews RB, Wetzel R: Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum Mol Genet 2002;11:2905-2917.
66. Apostol BL, Kazantsev A, Raffioni S, Illes K, Pallos J, Bodai L, Slepko N, Bear JE, Gertler FB, Hersch S, Housman DE, Marsh JL, Thompson LM: A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila. Proc Natl Acad Sci USA 2003;100:5950-5955.
67. Bates G: Huntingtin aggregation and toxicity in Huntington's disease. Lancet 2003;361: 1642-1644.
68. Sanchez I, Mahlke C, Yuan J: Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 2003;421:373-379.
69. Saudou F, Finkbeiner S, Devys D, Greenberg ME: Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 1998; 95:55-66.
70. Kim M, Lee HS, Laforet G, McIntyre C, Martin EJ, Chang P, Kim TW, Williams M, Reddy PH, Tagle D, Boyce FM, Won L, Heller A, Aronin N, DiFiglia M: Mutant huntingtin expression in clonal striatal cells: Dissociation of inclusion formation and neuronal survival by caspase inhibition. J Neurosci 1999;19:964-973.
71. Kuemmerle S, Gutekunst CA, Klein AM, Li XJ, Li SH, Beal MF, Hersch SM, Ferrante RJ: Huntington aggregates may not predict neuronal death in Huntington's disease. Ann Neurol 1999; 46:842-849.
72. Yu ZX, Li SH, Nguyen HP, Li XJ: Huntingtin inclusions do not deplete polyglutamine-containing transcription factors in HD mice. Hum Mol Genet 2002;11:905-914.
73. Cariello L, de Cristofaro T, Zanetti L, Cuomo T, Di Maio L, Campanella G, Rinaldi S, Zanetti P, Di Lauro R, Varrone S: Transglutaminase activity is related to CAG repeat length in patients with Huntington's disease. Hum Genet 1996;98:633-635.
74. Lesort M, Chun W, Johnson GV, Ferrante RJ: Tissue transglutaminase is increased in Huntington's disease brain. J Neurochem 1999;73:2018-2027.
75. Dedeoglu A, Kubilus JK, Jeitner TM, Matson SA, Bogdanov M, Kowall NW, Matson WR, Cooper AJ, Ratan RR, Beal MF, Hersch SM, Ferrante RJ: Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci 2002;22:8942-8950.
76. Karpuj MV, Becher MW, Springer JE, Chabas D, Youssef S, Pedotti R, Mitchell D, Steinman L: Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med 2002;8: 143-149.
77. Cooper AJ, Sheu KF, Burke JR, Onodera O, Strittmatter WJ, Roses AD, Blass JP: Polyglutamine domains are substrates of tissue transglutaminase: Does transglutaminase play a role in expanded CAG/poly-Q neurodegenerative diseases? J Neurochem 1997;69:431-434.
78. Jeitner TM, Bogdanov MB, Matson WR, Daikhin Y, Yudkoff M, Folk JE, Steinman L, Browne SE, Beal MF, Blass JP, Cooper AJ: N(epsilon)-(gamma-L- glutamyl)-L-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease. J Neurochem 2001;79:1109-1112.
79. Chun W, Lesort M, Tucholski J, Ross CA, Johnson GV: Tissue transglutaminase does not contribute to the formation of mutant huntingtin aggregates. J Cell Biol 2001;153:25-34.
80. Perutz MF, Johnson T, Suzuki M, Finch JT: Glutamine repeats as polar zippers: Their possible role in inherited neurodegenerative diseases. Proc Natl Acad Sci USA 1994;91:5355-5358.
81. Burke MG, Woscholski R, Yaliraki SN: Differential hydrophobicity drives self-assembly in Huntington's disease. Proc Natl Acad Sci USA 2003;100:13928-13933.
82. Chun W, Lesort M, Tucholski J, Faber PW, MacDonald ME, Ross CA, Johnson GV: Tissue transglutaminase selectively modifies proteins associated with truncated mutant huntingtin in intact cells. Neurobiol Dis 2001;8:391-404.
83. Mandrusiak LM, Beitel LK, Wang X, Scanlon TC, Chevalier-Larsen E, Merry DE, Trifiro MA: Transglutaminase potentiates ligand-dependent proteasome dysfunction induced by polyglutamine-expanded androgen receptor. Hum Mol Genet 2003;12:1497-1506.
84. Lesort M, Lee M, Tucholski J, Johnson GV: Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J Biol Chem 2003;278:3825-3830.
85. Cummings JL: Alzheimer's disease. N Engl J Med 2004;351:56-67.
86. Selkoe DJ: Alzheimer disease: Mechanistic understanding predicts novel therapies. Ann Intern Med 2004;140:627-638.
87. Johnson GV, Cox TM, Lockhart JP, Zinnerman MD, Miller ML, Powers RE: Transglutaminase activity is increased in Alzheimer's disease brain. Brain Res 1997;751:323-329.
88. Citron BA, SantaCruz KS, Davies PJ, Festoff BW: Intron-exon swapping of transglutaminase mRNA and neuronal Tau aggregation in Alzheimer's disease. J Biol Chem 2001;276: 3295-3301.
89. Monsonego A, Shani Y, Friedmann I, Paas Y, Eizenberg O, Schwartz M: Expression of GTP-dependent and GTP-independent tissue-type transglutaminase in cytokine-treated rat brain astrocytes. J Biol Chem 1997;272:3724-3732.
90. Bonelli RM, Aschoff A, Niederwieser G, Heuberger C, Jirikowski G: Cerebrospinal fluid tissue transglutaminase as a biochemical marker for Alzheimer's disease. Neurobiol Dis 2002;11: 106-110.
91. Nemes Z, Fesus L, Egerhazi A, Keszthelyi A, Degrell IM: N(epsilon)(gamma-glutamyl)lysine in cerebrospinal fluid marks Alzheimer type and vascular dementia. Neurobiol Aging 2001;22: 403-406.
92. Selkoe DJ, Abraham C, Ihara Y: Brain transglutaminase: In vitro crosslinking of human neurofilament proteins into insoluble polymers. Proc Natl Acad Sci USA 1982;79:6070-6074.
93. Miller CC, Anderton BH: Transglutaminase and the neuronal cytoskeleton in Alzheimer's disease. J Neurochem 1986;46:1912-1922.
94. Appelt DM, Balin BJ: The association of tissue transglutaminase with human recombinant tau results in the formation of insoluble filamentous structures. Brain Res 1997;745:21-31.
95. Murthy SN, Wilson JH, Lukas TJ, Kuret J, Lorand L: Cross-linking sites of the human tau protein, probed by reactions with human transglutaminase. J Neurochem 1998;71:2607-2614.
96. Tucholski J, Kuret J, Johnson GV: Tau is modified by tissue transglutaminase in situ: Possible functional and metabolic effects of polyamination. J Neurochem 1999;73:1871-1880.
97. Aeschlimann D, Paulsson M: Cross-linking of laminin-nidogen complexes by tissue transglutaminase. A novel mechanism for basement membrane stabilization. J Biol Chem 1991;266: 15308-15317.
98. Upchurch HF, Conway E, Patterson MK Jr, Maxwell MD: Localization of cellular transglutaminase on the extracellular matrix after wounding: Characteristics of the matrix bound enzyme. J Cell Physiol 1991;149:375-382.
99. Ikura K, Takahata K, Sasaki R: Cross-linking of a synthetic partial-length (1-28) peptide of the Alzheimer beta/A4 amyloid protein by transglutaminase. FEBS Lett 1993;326:109-111.
100. Dudek SM, Johnson GV: Transglutaminase facilitates the formation of polymers of the beta-amyloid peptide. Brain Res 1994;651:129-133.
101. Rasmussen LK, Sorensen ES, Petersen TE, Gliemann J, Jensen PH: Identification of glutamine and lysine residues in Alzheimer amyloid beta A4 peptide responsible for transglutaminase-catalysed homopolymerization and cross-linking to alpha 2M receptor. FEBS Lett 1994;338: 161-166.
102. Zhang W, Johnson BR, Suri DE, Martinez J, Bjornsson TD: Immunohistochemical demonstration of tissue transglutaminase in amyloid plaques. Acta Neuropathol (Berl) 1998;96:395-400.
103. Recchia A, Debetto P, Negro A, Guidolin D, Skaper SD, Giusti P: Alpha-synuclein and Parkinson's disease. FASEB J 2004;18:617-626.
104. Samii A, Nutt JG, Ransom BR: Parkinson's disease. Lancet 2004;363:1783-1793.
105. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL: Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276: 2045-2047.
106. Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R, Mizuno Y, Kosik KS, Selkoe DJ: Ubiquitination of a new form of alpha-synuclein by parkin from human brain: Implications for Parkinson's disease. Science 2001;293:263-269.
107. Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, Harta G, Brownstein MJ, Jonnalagada S, Chernova T, Dehejia A, Lavedan C, Gasser T, Steinbach PJ, Wilkinson KD, Polymeropoulos MH: The ubiquitin pathway in Parkinson's disease. Nature 1998;395:451-452.
108. Andringa G, Lam KY, Chegary M, Wang X, Chase TN, Bennett MC: Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson's disease. FASEB J 2004;18: 932-934.
109. Jensen PH, Sorensen ES, Petersen TE, Gliemann J, Rasmussen LK: Residues in the synuclein consensus motif of the alpha-synuclein fragment, NAC, participate in transglutaminase-catalysed cross-linking to Alzheimer-disease amyloid beta A4 peptide. Biochem J 1995;310(Pt 1):91-94.
110. Johnson GV, LeShoure R Jr: Immunoblot analysis reveals that isopeptide antibodies do not specifically recognize the epsilon-(gamma-glutamyl)lysine bonds formed by transglutaminase activity. J Neurosci Methods 2004;134:151-158.
111. Strong MJ: The basic aspects of therapeutics in amyotrophic lateral sclerosis. Pharmacol Ther 2003;98:379-414.
112. Bruijn LI, Houseweart MK, Kato S, Anderson KL, Anderson SD, Ohama E, Reaume AG, Scott RW, Cleveland DW: Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 1998;281:1851-1854.
113. Chou SM, Wang HS, Komai K: Colocalization of NOS and SOD1 in neurofilament accumulation within motor neurons of amyotrophic lateral sclerosis: An immunohistochemical study. J Chem Neuroanat 1996;10:249-258.
114. Stieber A, Gonatas JO, Gonatas NK: Aggregates of mutant protein appear progressively in dendrites, in periaxonal processes of oligodendrocytes, and in neuronal and astrocytic perikarya of mice expressing the SOD1(G93A) mutation of familial amyotrophic lateral sclerosis. J Neurol Sci 2000; 177:114-123.
115. Fujita K, Ando M, Yamauchi M, Nagata Y, Honda M: Alteration of transglutaminase activity in rat and human spinal cord after neuronal degeneration. Neurochem Res 1995;20:1195-1201.
116. Fujita K, Honda M, Hayashi R, Ogawa K, Ando M, Yamauchi M, Nagata Y: Transglutaminase activity in serum and cerebrospinal fluid in sporadic amyotrophic lateral sclerosis: A possible use as an indicator of extent of the motor neuron loss. J Neurol Sci 1998;158:53-57.
117. Holmes FE, Haynes LW: Superactivation of transglutaminase type 2 without change in enzyme level occurs during progressive neurodegeneration in the mnd mouse mutant. Neurosci Lett 1996;213:185-188.
118. Fujita K, Shibayama K, Yamauchi M, Kato T, Ando M, Takahashi H, Iritani K, Yoshimoto N, Nagata Y: Alteration of enzymatic activities implicating neuronal degeneration in the spinal cord of the motor neuron degeneration mouse during postnatal development. Neurochem Res 1998; 23:557-562.
119. Tetzlaff W, Gilad VH, Leonard C, Bisby MA, Gilad GM: Retrograde changes in transglutaminase activity after peripheral nerve injuries. Brain Res 1988;445:142-146.
120. Ientile R, Caccamo D, Marciano MC, Curro M, Mannucci C, Campisi A, Calapai G: Transglutaminase activity and transglutaminase mRNA transcripts in gerbil brain ischemia. Neurosci Lett 2004;363:173-177.